Performance Enhancing Drugs: A Rare Cause of Heart Failure

Daher, Ghassan; Hassanieh, Ihab; Malhotra, Nikhil; Neal, Christopher L.; Alderson, Lisa

doi:10.1016/s0735-1097(19)33220-6

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2019

Publication Types

Select...

Article1

Relationship

Self Cite1

Independent0

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is evident that as the serum level of T3 decreased, the hemodynamic support requirements decreased, and the cardiac function improved simultaneously (Table 1). Given the short half-life of T3 and its high protein binding capacity in circulation; dialysis, plasmapheresis, and binding agents had no therapeutic role [9].…”

Section: Discussionmentioning

confidence: 99%

Acute Decompensated Heart Failure Secondary to Exogenous Triiodothyronine Use in a Young Non-athlete Weightlifter

Daher

Hassanieh

Malhotra

et al. 2019

Cureus

Self Cite

View full text Add to dashboard Cite

Heart failure (HF) is a common cardiovascular disorder and is associated with increased morbidity and mortality. HF is usually detected in the elderly population, in particular, in patients with coronary artery disease, valvular disease, myocarditis, and hypertension. Acute decompensated HF in previously healthy young patients should raise suspicion for other rare etiologies. We report a case of a 28-year-old male presenting with acutely decompensated HF secondary to performance-enhancing drugs (PED). The use of non-regulated, non-approved PED has become a world-wide health problem with patients often unaware of the potentially serious and fatal side effects.

show abstract

Section: Discussionmentioning

confidence: 99%